UY25779A1 - Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovir - Google Patents
Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovirInfo
- Publication number
- UY25779A1 UY25779A1 UY25779A UY25779A UY25779A1 UY 25779 A1 UY25779 A1 UY 25779A1 UY 25779 A UY25779 A UY 25779A UY 25779 A UY25779 A UY 25779A UY 25779 A1 UY25779 A1 UY 25779A1
- Authority
- UY
- Uruguay
- Prior art keywords
- valacyclovir
- hydrochloride
- crystalline form
- valacyclovir hydrochloride
- anhydrous crystalline
- Prior art date
Links
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 title abstract 4
- 229940093257 valacyclovir Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 abstract 8
- 229940064636 valacyclovir hydrochloride Drugs 0.000 abstract 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 239000002904 solvent Substances 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 2
- 150000002576 ketones Chemical class 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000003158 alcohol group Chemical group 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- PQGVTLQEKCJXKF-RGMNGODLSA-N ethyl (2s)-2-amino-3-methylbutanoate;hydron;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)C(C)C PQGVTLQEKCJXKF-RGMNGODLSA-N 0.000 abstract 1
- 230000036571 hydration Effects 0.000 abstract 1
- 238000006703 hydration reaction Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501178.9A GB9501178D0 (en) | 1995-01-20 | 1995-01-20 | Guanine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25779A1 true UY25779A1 (es) | 2000-08-21 |
Family
ID=10768347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25779A UY25779A1 (es) | 1995-01-20 | 1999-10-29 | Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovir |
Country Status (40)
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501178D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Guanine derivative |
| CA2243237C (en) * | 1996-01-19 | 2008-09-02 | Glaxo Group Limited | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application |
| IT1283447B1 (it) * | 1996-07-18 | 1998-04-21 | Ind Chimica Srl | Processo di preparazione del valaciclovir e relativi intermedi |
| WO1998031683A1 (en) * | 1997-01-17 | 1998-07-23 | Ajinomoto Co., Inc. | Novel z-valacyclovir crystals |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| DE50209483D1 (de) * | 2001-02-24 | 2007-03-29 | Boehringer Ingelheim Pharma | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
| CA2457835A1 (en) * | 2001-09-07 | 2003-03-20 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of valacyclovir hydrochloride |
| AU2002348022B2 (en) * | 2001-11-05 | 2006-06-15 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| CA2465928C (en) * | 2001-11-14 | 2010-01-19 | Teva Pharmaceutical Industries Ltd. | Synthesis and purification of valacyclovir |
| EP1517678A2 (en) * | 2002-06-24 | 2005-03-30 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US20050043329A1 (en) * | 2002-09-06 | 2005-02-24 | Shlomit Wizel | Crystalline forms of valacyclovir hydrochloride |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| WO2004035583A1 (en) * | 2002-10-16 | 2004-04-29 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| CA2548608A1 (en) * | 2002-12-09 | 2004-06-24 | Texcontor Etablissement | Anhydrous crystalline form of valacyclovir hydrochloride |
| WO2004106338A1 (en) * | 2003-05-30 | 2004-12-09 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| EP2014660A3 (en) | 2003-06-02 | 2009-07-15 | Teva Pharmaceutical Industries Ltd | Novel crystalline forms of valacyclovir hydrochloride |
| WO2005073233A1 (en) * | 2004-01-21 | 2005-08-11 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of valacyclovir hydrochloride |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| CA2572268A1 (en) * | 2004-06-30 | 2006-02-02 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US20060178512A1 (en) * | 2005-02-04 | 2006-08-10 | Cheruthur Govindan | Method for preparing amino acid esters of nucleoside analogues |
| ATE546451T1 (de) * | 2005-05-25 | 2012-03-15 | Lilly Co Eli | Cyclopropancarbonsäureester von acyclovir |
| EP1746098A1 (en) | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20070112193A1 (en) * | 2005-11-14 | 2007-05-17 | Khunt Mayur D | Valacyclovir process |
| NZ600394A (en) * | 2006-05-04 | 2014-04-30 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CN1903854B (zh) * | 2006-08-09 | 2012-05-23 | 丽珠医药集团股份有限公司 | 一种合成盐酸伐昔洛韦的方法 |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| US20080281099A1 (en) * | 2007-05-07 | 2008-11-13 | Mayur Devjibhai Khunt | Process for purifying valacyclovir hydrochloride and intermediates thereof |
| GB0710277D0 (en) * | 2007-05-30 | 2007-07-11 | Univ Birmingham | Use of antivirals in the treatment of medical disorders |
| NZ600126A (en) * | 2007-08-17 | 2013-12-20 | Boehringer Ingelheim Int | Purine derivatives for use in the treatment of fap-related diseases |
| JPWO2009031576A1 (ja) * | 2007-09-03 | 2010-12-16 | 味の素株式会社 | バラシクロビル塩酸塩結晶の製造方法 |
| US20090076039A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched valacyclovir |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0917675A2 (pt) * | 2008-08-15 | 2015-12-01 | Boehringer Ingelheim Int | compostos orgânicos para cura de ferida |
| WO2010029089A2 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR20110103968A (ko) | 2008-12-23 | 2011-09-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 유기 화합물의 염 형태 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| KR20190071840A (ko) | 2009-11-27 | 2019-06-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| PH12012502162A1 (en) | 2010-05-05 | 2013-02-04 | Boehringer Ingelheim Int | Combination therapy |
| WO2011158252A1 (en) | 2010-06-15 | 2011-12-22 | Matrix Laboratories Ltd | Process for the preparation of valacyclovir hydrochloride polymorphic form ii |
| EP2585101A1 (en) | 2010-06-24 | 2013-05-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CN102584825B (zh) * | 2011-01-17 | 2014-04-02 | 四川科伦药物研究有限公司 | 一种合成盐酸伐昔洛韦的方法 |
| EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| EP2852592A4 (en) * | 2011-11-25 | 2015-12-23 | Piramal Entpr Ltd | PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849754B1 (en) | 2012-05-14 | 2022-09-14 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| KR102391564B1 (ko) | 2016-06-10 | 2022-04-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴 및 메트포르민의 병용물 |
| CN110437231B (zh) * | 2019-09-04 | 2022-04-29 | 上药康丽（常州）药业有限公司 | 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法 |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP55A (en) * | 1987-08-15 | 1989-09-26 | The Wellcome Foundation Ltd | Therapeutic Acyclic Nucleosides |
| ES2157259T3 (es) * | 1993-06-10 | 2001-08-16 | Rolabo Sl | Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos. |
| GB9501178D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Guanine derivative |
-
1995
- 1995-01-20 GB GBGB9501178.9A patent/GB9501178D0/en active Pending
-
1996
- 1996-01-19 SI SI9630717T patent/SI0804436T1/sl unknown
- 1996-01-19 ES ES96900631T patent/ES2248806T3/es not_active Expired - Lifetime
- 1996-01-19 SK SK965-97A patent/SK285329B6/sk not_active IP Right Cessation
- 1996-01-19 KR KR1019970704916A patent/KR100376074B1/ko not_active Expired - Lifetime
- 1996-01-19 AP APAP/P/1997/001058A patent/AP662A/en active
- 1996-01-19 DE DE69635106T patent/DE69635106T2/de not_active Expired - Lifetime
- 1996-01-19 CA CA002210799A patent/CA2210799C/en not_active Expired - Fee Related
- 1996-01-19 UA UA97084268A patent/UA46001C2/uk unknown
- 1996-01-19 AU AU44539/96A patent/AU702794B2/en not_active Ceased
- 1996-01-19 AR ARP960101082A patent/AR002270A1/es not_active Application Discontinuation
- 1996-01-19 HU HU9801836A patent/HU222993B1/hu not_active IP Right Cessation
- 1996-01-19 ZA ZA96449A patent/ZA96449B/xx unknown
- 1996-01-19 US US08/875,173 patent/US6107302A/en not_active Expired - Lifetime
- 1996-01-19 NZ NZ298851A patent/NZ298851A/xx not_active IP Right Cessation
- 1996-01-19 EE EE9700175A patent/EE03528B1/xx not_active IP Right Cessation
- 1996-01-19 IL IL11683196A patent/IL116831A/en not_active IP Right Cessation
- 1996-01-19 IN IN102MA1996 patent/IN182468B/en unknown
- 1996-01-19 EP EP96900631A patent/EP0804436B1/en not_active Expired - Lifetime
- 1996-01-19 RO RO97-01334A patent/RO118693B1/ro unknown
- 1996-01-19 FI FI973063A patent/FI973063A7/fi not_active Application Discontinuation
- 1996-01-19 TR TR97/00656T patent/TR199700656T1/xx unknown
- 1996-01-19 RS YU3396A patent/RS49518B/sr unknown
- 1996-01-19 CZ CZ0229497A patent/CZ297065B6/cs not_active IP Right Cessation
- 1996-01-19 AT AT96900631T patent/ATE302777T1/de not_active IP Right Cessation
- 1996-01-19 GE GEAP19963845A patent/GEP20001940B/en unknown
- 1996-01-19 WO PCT/GB1996/000117 patent/WO1996022291A1/en not_active Ceased
- 1996-01-19 EA EA199700124A patent/EA000364B1/ru not_active IP Right Cessation
- 1996-01-19 CN CN96192662A patent/CN1049893C/zh not_active Expired - Fee Related
- 1996-01-19 PL PL96321326A patent/PL182175B1/pl not_active IP Right Cessation
- 1996-01-19 HR HR960024A patent/HRP960024B1/xx not_active IP Right Cessation
- 1996-01-19 JP JP52213196A patent/JP3176633B2/ja not_active Expired - Fee Related
- 1996-01-19 BR BR9606768A patent/BR9606768A/pt active IP Right Grant
- 1996-01-19 DK DK96900631T patent/DK0804436T3/da active
-
1997
- 1997-07-15 IS IS4527A patent/IS2268B/is unknown
- 1997-07-16 OA OA70051A patent/OA10499A/en unknown
- 1997-07-18 NO NO19973326A patent/NO315558B1/no not_active IP Right Cessation
- 1997-08-14 BG BG101833A patent/BG63393B1/bg unknown
-
1999
- 1999-10-29 UY UY25779A patent/UY25779A1/es not_active IP Right Cessation
-
2005
- 2005-11-16 CY CY0500061A patent/CY2531B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25779A1 (es) | Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovir | |
| ES2153343T3 (es) | Procedimiento para la preparacion de derivados de purina. | |
| CO4950563A1 (es) | Nuevos compuestos | |
| KR890003761A (ko) | 치료학적 아시클릭 뉴클레오시드 | |
| AR041679A1 (es) | Compuestos polimorfos de mesilato de imatinib | |
| ES532880A0 (es) | Un procedimiento para obtener composiciones farmaceuticas que contienen un derivado del acido 3-hidroxibutanoico y de una base inorganica u organica nitrogenada. | |
| CO5040054A1 (es) | Metodo para preparar y purificar un derivado de aspartame n-alquilatado | |
| BR0210333A (pt) | catalisador de rutênio, processos para preparar o mesmo e álcoois de açúcar por hidrogenação catalìtica dos monossacarìdeos e oligossacarìdeos correspondentes, e, uso de um catalisador | |
| ES2272068T3 (es) | Mejoras en la produccion de macrolidas. | |
| AR051778A2 (es) | Derivados del acido dimetilaminocrotonico y procesos para supreparacion | |
| ES2170732B2 (es) | Procedimiento para preparar citalopram purificado | |
| DK1412083T3 (da) | Fremgangsmåde til fremstilling af sorbitol ved hydrogenering af egnede monosaccharider på en Ru/Sio2-katalysator | |
| KR970703342A (ko) | 아자비시클릭 유도체의 제조 방법(Process for The Preparation of Azabicyclic Derivatives) | |
| BR0316829A (pt) | Processo contìnuo para a preparação de álcoois de açúcar | |
| NO20014347L (no) | Synergistisk inhibering av viral replikasjon ved langkjedede hydrokarboner og nukleosidanaloger | |
| HUP0002754A2 (hu) | (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol-hemiszulfát, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény, valamint intermedierek | |
| CO4750651A1 (es) | Compuesto activo farmacologicamente | |
| HU205131B (en) | Process for producing dexylosyl derivatives of antibiotics of group bu-3608, as well as pharmaceutical compositions comprising such compounds | |
| AR240878A2 (es) | Un procedimiento para preparar un silicato de aluminio cristalino compuesto | |
| US4349466A (en) | Peptide, process for preparation thereof and use thereof | |
| RU2003119451A (ru) | Способ получения 1-(аминометил) циклогексануксусной кислоты | |
| BR1101133A (pt) | Derivado de sinergistina, (quinuclidinil-3(s) tiometil-5 bem como seus sais farmaceuticamente aceitáveis, processo de preparação do derivado de sinergistina e composição farmacêutica | |
| ES2133351T3 (es) | Uso de un tioester para preparar composiciones farmaceuticas destinadas al tratamiento de sindromes de isquemia y de reperfusion. | |
| PE20000271A1 (es) | Composicion farmaceutica de (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenteno-1-metanol | |
| MXPA04006391A (es) | Procesos para preparar calcio de mupirocina cristalina y amorfa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20191029 |